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The non-steroidal anti-inflammatory drugs (NSAIDs) as the name implies are compounds of non-
steroidal origin, with the capability of inhibiting/reducing inflammatory response associated with tissue 
injury which could be as a result of physical trauma, noxious chemicals or microorganisms. There is 
however reason to believe that these drugs, which confound disease progression by suppressing fever, 
pain and attenuating some of the cardinal manifestations of inflammation in a patient actually lessen 
the immunologic response to bacterial infection. This seemingly paradoxical property is the birth of this 
mini review. This review aims at invalidating the claims that NSAIDs in general lessen the 
immunological response to microbial infections by examining the antimicrobial properties of diclofenac 
sodium, an NSAID. 
 





Increased interest in NSAIDs, traditionally known as the 
analgesic-antipyretics came with the discovery of their 
profound anti-inflammatory properties. The discovery 
afforded the opportunity to have a single drug therapy 
that would alleviate the problems of pain, fever and in-
flammation frequently associated with many underlying 
disease conditions. In the last decade, there has been 
renewed interest in NSAIDs and surprisingly this does not 
stem from their traditional properties or uses, but as a 
result of new properties, which they may possess. Inflam-
mation is a body’s normal protective response to tissue 
injury. It is the body’s effort to inactivate or destroy inva-
ding microorganisms, remove irritants and set the stage 
for tissue repair. When healing is complete though, the 
inflammatory process usually subsides (Mycek et al., 
2000). Sometimes however, the defense reactions 
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of arthritis requiring anti-inflammatory (or immunosup-
pressive) drugs to modulate the inflammatory process 
(Mycek et al., 2000; Payan and Katzung, 1995). Also 
local and systematic inflammations such as those elicited 
by bacterial infections at mucosal surfaces are often 
times treated with NSAIDs in combination with other 
drugs. However, the use of anti-inflammatory therapy has 
been questioned on the basis that such treatment may 
compromise the immune function. Several reports have 
implicated NSAIDs as having actions that may lessen 
immunological response to bacterial infections (File, 
2003; Linder et al., 1990; Stevens, 1995) and as such 
while confounding the progression of disease by sup-
pressing inflammation, fever and pain, they could actually 
be enhancing the progression of bacterial infection. 
 
 
THE INFLAMMATORY RESPONSE 
 
Inflammation is a general, non-specific reaction to foreign 
particles and other noxious stimuli such as toxins and 





invading organisms, remove irritants and set the stage for 
tissue repair (Madigan et al., 2000). Characteristics of the 
inflammatory response include redness, swelling, pain 
and heat which are localized at the site of infection (Furr, 
1992). Even though inflammation is a non-specific immu-
nological reaction, it employs specific cell mediated 
immunological responses such as the leukocytes and 
their cytokine secretions, which mediate on inflammatory 
reactions. Inflammation is triggered by the release of 
chemical mediators from injured tissues and migrating 
cells. The specific chemical mediators vary with the type 
of inflammatory process and include amines e.g. hista-
mines and 5-hydroxytryptamine lipids e.g. prostaglandins, 
small peptides such as bradykinin and larger peptides 
such as interleukin-1, which is a cytokine (Furr, 1992; 
Mycek et al., 2000). Most NSAIDs act by inhibiting the 
synthesis of prostaglandins. Thus, understanding of 
NSAIDs require a comprehension of the actions of 
prostaglandins. 
Prostaglandins (PGs) and related fatty acid derivatives 
of arachidonic acid are among the most potent naturally 
occurring autacoids. They are critically important cell 
regulatory substances (Rang et al., 1999). The PGs and 
several other biologically active lipids and peptidolipid 
acids are formed from the same precursor (arachidonic 
acid) through interrelated enzymatic pathways. These 
other lipids are nearly all carboxylic acids and include the 
thromboxanes (TXs), the hydroxyeicosatetraenoic acids 
(HETEs), the leukotrienes (LTs), most recently dis-
covered lipoxins (LXs) and epoxyeicosatetraenoic acids 
(EETEs). They are generally known as the Eicosanoids 
(Hecker et al., 1995). Free arachidonic acid is meta-
bolized mainly by two divergent enzymatic pathways that 
are variably distributed among different cells: the cyclo-
oxygenase (COX) and the lipoxygenase pathways 
(Mycek et al., 2000; Payan and Katzung, 1995; Rang et 
al., 1999). The products of the cyclooxygenase pathway 
are the ring structured eicosanoids (PGs, TXs and Pros-
tacyclines) catalyzed by two enzymes COX-1 and COX-
2. The COX-2 appears to be the form of the enzyme 
associated with cells involved in the inflammatory 
process. The COX-1 is a constitutive enzyme expressed 
in most tissues including blood platelets. It is involved in 
cell-cell signaling and in tissue homeostasis (Rang et al., 
1999). Clearly, the anti-inflammatory action of NSAIDs is 
mainly related to their inhibition of COX-2. Most of the 
undesirable effects of NSAIDs have been suggested to 
result from their inhibition of the COX-1 enzymatic 
pathway (Payan and Katzung, 1995). The lipoxygenase 
pathway is catalyzed mainly by 5-lipoxygenase enzyme. 
The products of this pathway are the 5-HPETE, 12-HPE 
TE and HPETE, which are unstable and converted to the 
HETEs or to leukotrienes or lipoxins depending on the 
tissues (Mycek et al., 2000). 
Prostaglandins and related compounds are produced in 
minute quantities by virtually all tissues. They generally 
act on the tissues in which they are synthesized  and  are  




rapidly metabolized into inactive products at their sites of 
action. Thus, the PGs do not circulate in the blood in 
significant concentrations (Mycek et al., 2000). In gene-
ral, prostaglandins have a variety of effects on smooth 
muscles, platelets, reproductive system, central nervous 
system and on cells involved in inflammation. The leuko-
trienes are present in the tissues in many inflammatory 
conditions. They have a powerful chemotactic effect on 
eosinophils, neutrophils and macrophages. They promote 
broncho-constriction and alter vascular permeability. The 
prostaglandins are not chemo-attractants, but the 
leukotrienes and some of the HETEs are strong chemo-
attractants (Hecker et al., 1995). 
The primary inflammatory cytokines are important co-
players when COX-2 is induced in inflammatory cells. 
They regulate cyclooxygenase and lipoxygenase enzy-
matic activities (Hecker et al., 1995; Rang et al., 1999b) 
hence they shall be discussed briefly. As mentioned 
earlier, there are other chemical mediators that play 
important roles in the inflammatory processes. Their dis-
cuss, however, is outside the scope of this work. The 
cytokines are another group of chemo-attractants 
produced by leukocytes. They are, by nature, proteins 
and are responsible for recruiting and activating non-
specific effector cells such as the phagocytes (Madigan 
et al., 2000). They are released from inflammatory 
tissues, connective tissues and immune system cells. 
They act by autocrine and paracrine mechanisms in a 
manner somewhat similar to hormonal actions. In most 
instances, cytokine effects are modulated via cell surface 
receptors on target cells. Cytokines are known to have 
anti-proliferative and antimicrobial activities (Salmon et 
al., 1995). For example, infections with Gram negative 
[G-ve] bacteria induce inflammatory response that could 
be local or systemic (De Man et al., 1988; Gilbert, 1992). 
The inflammation is elicited by whole bacterium and lipid 
A moiety of lipopolysaccharide (LPS) on the surfaces of 
G-ve bacteria (De Man et al., 1989; Hagbery et al., 1983; 
Rietschel et al., 1982). The LPS induces the recruitment 
of a wide range of cytokines, such as the tumour necrosis 
factor, (TNF), Interleukin-1 (IL-1), IL-6 and colony stimu-
lating factors (CSFs) (Dinarello et al., 1988; Nijsten et al., 
1987; Perimutter et al., 1986). More than 50 cytokines 
have been identified to date and their super families 
include interleukins, chemokines, colony-stimulating 
factors, growth factors, interferons, transforming growth 
factors (TGF) and the tumour necrosis factors (TNFs). 
They have varied actions. Some are pro-inflammatory 
cytokines and include the TNF and interleukin-1 (IL-1). 
The anti-inflammatory cytokines include TGF-B, IL-4, IL-
10 and IL-13. 
The inflammatory response is a reflection of the seve-
rity of disease (De Man et al., 1989). It can be quantitated 
by the recruitment of the acute phase reactants, pyro-
gens, chemoattractants such as cytokines and the poly-
morphonuclear leukocytes (PMNL) (Linder et al., 1990; 
Shahin et al., 1987). The assay of IL-6  as  a  measure  of  




inflammation is particularly preferred though, this is based 
mainly on the accuracy of the assay. The hybridoma 
assay for IL-6 has a high degree of specificity (De Man et 
al., 1989). In contrast, some commonly used assays such 
as the human-urine IL-1 have had their validity being 
debated over (Helle et al., 1988; Nelle et al., 1988). 
 
 
THE ROLE OF NSAIDS IN THE INFLAMMATORY 
RESPONSE 
 
As earlier mentioned, NSAIDs act by blocking prosta-
glandin and thromboxane synthesis. This is achieved 
through the inhibition of the cyclooxygenase pathway 
which is responsible for their synthesis. With a few 
exceptions, NSAIDs do not inhibit lipoxygenase activity at 
concentrations that markedly inhibit cyclooxygenase 
activity (Hecker et al., 1995). Since the lipoxygenase and 
cyclooxygenase pathways have the same precursor 
(arachidonic acid), inhibiting the metabolism of arachi-
donic acid via the cycloxygenase pathway would cause 
metabolism to tend more to the lipoxygenase pathway; 
thus causing more products formation than usual via that 
pathway. Hence, the use of NSAIDs leads to an increase 
in the formation of inflammatory leukotrienes. It has been 
discovered that even among the cyclooxygenase depen-
dent pathways, inhibiting the synthesis of one derivative 
may increase the synthesis of an enzymatically related 
product. This is however not usually desirable as the 
thromboxanes and leukotrienes are known to be ‘patho-
logic eicosanoids’ (Hecker et al., 1995). The activities of 
prostaglandins and leukotrienes in the body produce 
somewhat opposite effects. Prostaglandin-E2 (PGE2) and 
PGI2 are the two common prostaglandins synthesized in 
humans. PGE2 inhibits the activation and proliferation of 
B-lymphocytes by T-lymphocytes (CD4+) while leuko-
triene-B4 (LTB4) stimulates it while inhibiting both antigen-
driven and mitogen-induced B-lymphocyte proliferation 
and differentiation to plasma cells. This results in the 
inhibition of immunoglobulin M (lgM) synthesis and en-
hanced class switch to IgE. PGE2 and possibly PGI2 
inhibit the expression of IL-1 and its effect on T-lympho-
cytes, while LTB4 and LTD4 increase its expression. 
PGE2 and probably PGI2 inhibit interferon gamma (INT-) 
activity on macrophages, while LTB4, LTC4 and LTD4 
stimulate it. Also PGE2 and possibly PGI2 inhibit the 
action of IL-2 from CD4+ lymphocytes to CD8+, LTB4 does 
the reverse (Hecker et al., 1995; Salmon et al., 1995). It 
can thus be inferred that the blockage of the cyclo-
oxygenase pathway leads to the increased activity of the 
lipoxygenase pathway. Diclofenac and indomethacin 
have however been reported to reduce synthesis of both 
prostaglandins and leukotrienes (Payan and Katzung, 
1995) and consequently the increased expression of the 
cytokines (Figure 1). The analgesic and antipyretic 
actions of NSAIDs are attributed to PGE inhibition. Also 





renal blood flow properties of NSAIDs are attributed to 
inhibition of PG synthesis (Mycek et al., 2000; Payan and 
Katzung, 1995). It should be mentioned however that 
corticosteroids have the unique ability of blocking 
simultaneously the cyclooxygenase and lipoxy-genase 
pathways. This is achieved by inhibition of the 
phospholipase activity (that is, the enzyme that catalyzes 
arachidonic acid synthesis). This would invariably inhibit 
both cyclooxygenase and lipoxygenase pathways. 
 
 
THE ANTIBACTERIAL PROPERTY OF DICLOFENAC 
 
In recent years, due to the increased resistance of many 
bacteria to the commonly used antimicrobial agents, 
attention has shifted to drugs belonging to different phar-
macological classes for possible antimicrobial activity. 
This, borne out of the fact that a single drug may have 
varying properties with diverse physiological activities 
and functions and as a result, may have useful activities 
in completely different spheres of medicine. This, in turn, 
has led to the investigation of drugs belonging to different 
pharmacological classes for possible antimicrobial 
activity. At present, drugs from various pharmacological 
classes such as promethazine-an antihistamine, proma-
zine-a psychotropic agent, methyledopa - a local anaes-
thetic, dobutamine -a cardiovascular drug and diclofenac, 
an NSAID, have been discovered to possess potent anti-
microbial activities (Annaduri et al., 1998; Chakrabarty et 
al., 1989; Chattopadhyay et al., 1988; Dash et al., 1977; 
Dastidar et al., 1976; Dastidar et al., 1986; Dastidar et al., 
2003) and are now referred to as “non-antibiotics” 
(Kristiansen, 1992). 
In a trial experiment carried out in our laboratory on the 
in vitro antimicrobial activity of Diclofenac sodium using 
the bore-hole method on Mueller-Hinton agar (CM337 
Oxoid), Diclofenac sodium was found to possess consi-
derably good antimicrobial properties, on incubating for 
24 h at 37˚C, as shown in Table 1. In other recorded 
studies, concentrations of diclofenac sodium (50-100 ug/ 
ml) have been shown to possess in vitro activity against 
most bacteria (Annaduri et al., 1998). In vitro assays 
using 30 - 50 /20 g mouse have also been shown to 
possess appreciable antibacterial activity against virulent 
Salmonella typhimurium strains (Dastidar et al., 2000). 
Though much about the mechanism of activity is still not 
very clear, some have attributed it to be a result of the 
inhibition of DNA synthesis in bacterial cells (Dastidar et 
al., 2000). In this report the anti-bacterial action of 
Diclofenac was found to be due to the inhibition of DNA 
synthesis which was demonstrated using 2 µ Ci(3H) 
deoxythymidine uptake. In the light of this, could 
diclofenac join other drugs such as bleomycin and doxo-
rubicin as anti-tumour antibiotics? Further work would 
have to be done to ascertain the possibility of this. It has 
however been proven to be a drug with great potential for 
use as an antimicrobial agent. 






Figure 1. The funneling of substrate between the cyclooxygenase and lipoxygenase pathways. The cyclooxygenase pathway involves the prostaglandin and thromboxane biosynthesis. The 
asterisks for the cycooxygenase pathway indicate that the cyclooxygenase and peroxidase steps are catalyzed by a single enzyme, prostaglandin endoperoxide (PGH) synthase. The 
lipoxygenase pathway involves leukotriene biosynthesis. The asterisks in this pathway indicate that both the lipoxygenase and dehydrase reactions are driven by the single enzyme, 5-
lipoxygenase (GGTP, -glutamyltranspeptidase (Modified from Foegh and Ramwell, 2001). 















E. coli 9637 106 2.5 mg 14 (cidal) 
P. aeruginosa 27853 106 2.5 mg 8 (cidal) 
S. typhi 13709 106 2.5 mg 13 (cidal) 




ACTIVITY ON BIOFILMS 
 
In addition to having antimicrobial properties, diclo-
fenachas recently been discovered to inhibit microbial 
biofilms. A biofilm is a population of cells growing on a 
surface and enclosed in an exopolysaccharide matrix 
(Lewis, 2000; Lewis, 2001). Biofilms confer resistance on 
micro-organisms to antibiotic treatment (Brooun et al., 
2000; Costerton et al., 1995; Douglas and Ballie, 1998; 
Gander, 1996). The development of resistance by 
microorganisms to antimicrobial drugs has been one of 
the greatest problems hampering antimicrobial therapy 
(Olaniyi, 1989). Bacterial biofilms show enormous levels 
of antibiotic resistance. In fact, resistance to 
antimicrobials is a general feature of all biofilms (Brooun 
et al., 2000; Douglas and Ballie, 1998). Biofilms are the 
major cause of recalcitrant infections and might be 
responsible for 65% of all bacterial infections (Brooun et 
al., 2000; Costerton et al., 1999; Potera, 1999). Candida 
albicans, a major fungal pathogen of humans (Cox and 
Perfect, 1993) has been discovered to form biofilms 
(Douglas and Ballie, 1998; Hawser and Douglas, 1994). 
Others include Staphylococcus spp, Pseudomonas spp 
and Escherichia coli (Aries et al., 1999; Brooun et al., 
2000; Lewis, 2000; Lewis, 2001). Most susceptibility 
studies done on biofilms are on preformed biofilms and 
not on the ability of a biofilm to grow, hence 
antimicrobials reported to inhibit biofilm growth are those, 
which are able to diffuse through the preformed biofilms 
and exert their actions (Lewis, 2001). Examples include 
the fluroquinolones, cephalosporins, rifampicin. The 
problem with these measurements is that the results are 
not entirely conclusive. Functional tests for growth could 
be a better assay protocol for biofilm susceptibility to 
antibiotics. 
In one experimental model, viability assays were car-
ried out on both growing and fully mature (48 h cultures) 
biofilms to investigate the effects of aspirin, diclofenac 
and other NSAIDs on biofilm formation (Alem and 
Douglas, 2004). Results showed that diclofenac, aspirin 
and etodolac had the greatest inhibitory effect, with 
aspirin causing up to 95% inhibition. Celecoxib, nime-
sulide, ibuprofen and meloxican also inhibited biofilm 
formation, but to a lesser extent. The inhibition of prosta-
glandin synthesis was suggested to be the mode of 
action of NSAIDs on the inhibition of biofilm formation. On 
the other hand, Diclofenac was reported to inhibit signifi-
cantly germ tube formation, in addition to inhibiting biofilm 
formation - a feature not expressed by aspirin (Alem and 
Douglas, 2004). Could this additional feature be a 
function of diclofenac’s antimicrobial action on Candida 
albicans (Costerton et al., 1999)? Biofilms are resistant to 
the immune system as a result of their exopoly-
saccharides (Hoyle et al., 1990). It could then be inferred 
that Diclofenac would be a good therapeutic agent for 
treating persistent or relapsing bacterial and fungal 
infections. It is however recommended that further in-
vestigations be carried out on the inhibition of biofilm 
formation using other potent prostaglandin inhibitors such 
as corticosteroids, since the inhibition of prostaglandin 
synthesis was suggested (Alem and Douglas, 2004) to be 
NSAIDs’ mechanism of inhibiting biofilm formation. 
 
 
THE UNUSUAL SUSPECT 
 
The use of NSAIDs has been previously perceived as 
one that would not alter patient responses to infection 
(Payan and Katzung, 1995). Bacterial infections induce 
inflammatory responses which sometimes require anti-
inflammatory therapy. The use of NSAIDs is particulary 
favoured because unlike the corticosteroids which con-
found host immunity (Salmon et al., 1995), NSAIDs are 
generally perceived as not having actions that com-
promise immunity. This has greatly encouraged their use 
in bacterial induced inflammation and other inflammatory 
conditions which require long term treatment or in which 
host immunity is likely to be threatened by use of 
corticosteroids. Some more recent reports have however 
implicated NSAIDs as having actions that may enhance 
the progression of bacterial infections (Barnham and 
Anderson, 1997; Smith and Berk, 1991; Stevens, 1995). 
There is reason to believe that NSAIDs have several 
actions that may lessen the immunologic response to 
bacterial infections. That by their actions, such as 
impairment of granulocyte function (adherence, phago-
cytosis, cidal activity), augmentation of inflammatory 
cytokine release and inhibition of renal prostaglandin syn-
thesis, NSAIDs confound the remission of disease (File, 
2003). Reports have implicated NSAIDs as predisposing 
factors to bacterial infections (Stevens, 1995).  





(that is, inhibition of PG synthesis by NSAIDs) results in 
increased leukotriene synthesis, which in turn favours 
cytokine release (e.g. PGE2 and PGI2 have inhibitory 
effect on IL-1 production, while LTB4 has reverse effect), 
it has, on the other hand, been suggested as a mecha-
nism by which NSAIDs lessen the immunological response 
to bacterial infections (others have cited that the inflam-
matory response quantitated as the recruitment of PMNL 
and increased level of cytokines coincides with the clea-
rance of infection) (File, 2003). These reports suggested 
that cytokine release and consequently inflammation is 
responsible for the elimination of bacteria and infection 
(Coulie et al., 1987). Further explanations suggest that 
the inhibition of inflammation impairs bacterial clearance 
from the kidneys. Suggestions have however been made 
that the impairment of bacterial clearance as a result of 
inhibition of inflammation is not a direct function of the 
inhibited cytokine (IL-6) or PMNL recruitment (Linder et 
al., 1990). Indomethacin (an NSAID) was experimented 
upon and found to reduce bacterial clearance (Linder et 
al., 1988). Similar experiments using diclofenac also pro-
duced a reduction in bacterial clearance, although the 
concentrations used to produce this effect were very high 
and lower (normal) concentrations did not reduce bac-
terial clearance (Linder et al., 1990). In another experi-
ment on the influence of antiinflammatory therapy on 
bacterial clearance, the finding was that; following intra-
mammary E. coli challenge in glands, non-steroidal anti-
inflammatory therapy did not adversely influence the 
clearance of E. coli from challenged glands (Anderson et 
al., 1991). 
In another development, diclofenac was reported to 
protect rabbits from necrotizing fasciitis caused by Group 
A Streptococcus (GAS) (Guibal et al., 1998). Reports 
have also shown diclofenac not to adversely affect thera-
py when used in combination with anti-tubercular drugs in 
treatment of Mycobacterium avium complex (MAC) (Sano 
et al., 1999). Moreover in this report, diclofenac in combi-
nation with the anti-tubercular drug used had higher clea-
rance of MAC from the lungs although it was not signifi-
cantly different (p < 0.001) from reduction in bacterial 




CAN A NON-STEROIDAL ANTI-INFLAMMATORY 
DRUG WITH ANTIMICROBIAL PROPERTIES, REDUCE 
IMMUNOLOGIC RESPONSE TO BACTERIAL 
INFECTIONS? 
 
It is still not an established fact that NSAIDs lessen the 
immunologic response to bacterial infections. Though the 
anti-inflammatory drugs; dexamethasone (a cortico-
steroid), diclofenac and indomethacin (NSAIDs) have 
been reported to decrease bacterial clearance from 
kidneys of E. coli infected mice (Linder et al., 1990). Con-
trasting reports state that anti-inflammatory therapy did 
not adversely influence  clearance  of  E. coli  from  chall-  




enged glands (Anderson et al., 1991) in goats. Reports 
based on experimental data have even suggested that 
the administration of diclofenac after infection protected 
rabbits from necrotizing fasciitis caused by Group A 
Streptococcus (GAS) and that diclofenac did not potentiate 
tissue damage (Guibal et al., 1998). 
There is good reason to believe that anti-inflammatory 
therapy may compromise immune function and this is 
particularly true of the corticosteroids. They are known 
not only to greatly reduce inflammation, but also immune 
response. They decrease the concentration of lympho-
cytes (B and T cells), basophils, eosinophils, monocytes 
and bring about inhibition of the ability of leukocytes and 
macrophages to respond to mitogens and antigens 
(Mycek et al., 2000). Steroids relieve inflammation by 
inhibiting the synthesis of arachidonic acid and cones-
quently its metabolism via both lipoxygenase and cyclo-
oxygenase pathways. Thus, the action of steroids greatly 
reduces cell mediated and inflammatory responses 
(Salmon et al., 1995). NSAIDs on the other hand inhibit 
the metabolism of arachidonic acid only through the 
cyclooxygenase pathway. The lipoxygenase pathway is 
left functional and hence the production of leukotrienes 
and cytokine expression (Figure 1). A good reference to 
this has been discussed (Barnham and Anderson, 1997) 
where dexamethasone on administration was found to 
reduce both interleukin (IL-6) secretion and PMNL res-
ponse while indomethacin was found not to decrease 
neither IL-6 secretion nor PMNL response. Diclofenac 
was found to decrease IL-6 levels in the urine, but not in 
serum (Barnham and Anderson, 1997). Diclofenac and 
indomethacin were found to significantly increase IL-6 
levels after 24 h treatment (IL-6 secretion was reported to 
coincide with bacterial clearance) (Barnham and 
Anderson, 1997). With reference to Figure 1, it can be 
inferred that treatment with NSAIDs does not block the 
inflammatory immune response to bacterial infections. 
Diclofenac was mentioned not to decrease bacterial clea-
rance at lower (therapeutic) but only at higher concen-
trations. These high concentrations are however exag-
gerated and may be toxic.  
It should be mentioned that inflammation might actually 
promote bacterial growth. Inflammation leads to fluid 
accumulation in the area of injury due to increased 
permeability, this leads to localized oedema, which may 
actually promote bacterial growth (Fur, 1992). Another 
means by which it may aid microbial pathogenesis is 
borne out of the fact that the inflammatory response eli-
cited by an invading organism can result in considerable 
host damage, making nutrients available and providing 
access to host tissues (Madigan et al., 2000), hence the 





1) Do NSAIDs in general lessen immunologic response to  




bacterial infections, or is it a property peculiar to some? 
2) Do they decrease bacterial clearance or is this also 
peculiar to some? 
3) Does the level of selective inhibition of COX-1 and 
COX-2 affect the immunologic response to infections? 
 
The therapeutic benefits of having one drug as an 
analgesic, antipyretic, anti-inflammatory and an anti-
microbial should be greatly explored. Further work would 
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